COVID-19

Nanox.AI Connects to Nuance Precision Imaging Network to Improve Early Detection of Chronic Diseases with Workflow-Integrated AI

The secure nationwide AI-powered cloud platform streamlines care team communication and delivers patient-specific imaging insights within clinical workflowsNEVE ILAN, Israel,...

Aligos Therapeutics to Present Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver

SOUTH SAN FRANCISCO, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

Quipt Home Medical Reports Record First Quarter Fiscal 2023 Financial Results Posting Positive Net Income, Revenue Growth of 38% and Adjusted EBITDA Growth of 50%

Posts Strong Adjusted EBITDA Margin of 22% and Sequential Organic Growth of 2%CINCINNATI, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Quipt...

Monopar Announces Camsirubicin Clinical Program Update – Improved Side Effect Profile Seen to Date Compared to Doxorubicin

WILMETTE, Ill., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary...

Hyperfine, Inc. Announces FDA Clearance for Improved AI-Powered Software and Expanded Field of View for the Swoop® Portable MR Imaging® System

Latest Swoop® software improves image quality for DWI imaging of the brainGUILFORD, Conn., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Hyperfine,...

Acer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

Topline trial results expected mid-March 2023NEWTON, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical...

Panbela Announces Closing of Approximately $15 Million Public Offering, and Regains Compliance with Nasdaq Listing Standards

MINNEAPOLIS, Minn, Feb. 13, 2023 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive...

Akari Therapeutics Announces Acceleration of the Phase 3 Clinical Trial of Nomacopan for Treatment of Pediatric HSCT-TMA into Pivotal Part B and Addition of a New Pipeline Program Developing Nomacopan for HSCT-TMA in Adults

Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ACU193, First Monoclonal Antibody Developed to Selectively Target Toxic Aβ Oligomers in Patients with Early Alzheimer’s Disease

Topline results including safety and proof-of-mechanism data expected in third quarter of 2023CHARLOTTESVILLE, Va. and CARMEL, Ind., Feb. 13, 2023...

Ocuphire Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol® Eye Drops for Reversal of Mydriasis

If Approved Later This Year, Nyxol Could be the Only Commercially Available Eye Drop for Reversal of DilationFARMINGTON HILLS, Mich.,...

error: Content is protected !!